These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 26087179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8.
    Li F, Zhang X, Gordon JR.
    Biochem Biophys Res Commun; 2002 May 10; 293(3):939-44. PubMed ID: 12051749
    [Abstract] [Full Text] [Related]

  • 4. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.
    J Leukoc Biol; 2005 Dec 10; 78(6):1265-72. PubMed ID: 16204619
    [Abstract] [Full Text] [Related]

  • 5. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.
    Zhao X, Li F, Town JR, Zhang X, Wang W, Gordon JR.
    Int Immunopharmacol; 2007 Dec 15; 7(13):1723-31. PubMed ID: 17996682
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels.
    Zhao X, Town JR, Li F, Zhang X, Cockcroft DW, Gordon JR.
    J Immunol; 2009 Mar 01; 182(5):3213-22. PubMed ID: 19234219
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The antagonist of CXCR1 and CXCR2 protects db/db mice from metabolic diseases through modulating inflammation.
    Cui S, Qiao L, Yu S, Men L, Li Y, Li F, Du J.
    Am J Physiol Endocrinol Metab; 2019 Dec 01; 317(6):E1205-E1217. PubMed ID: 31573846
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity.
    Li L, Khan MN, Li Q, Chen X, Wei J, Wang B, Cheng JW, Gordon JR, Li F.
    Oncol Rep; 2015 Feb 01; 33(2):751-7. PubMed ID: 25504010
    [Abstract] [Full Text] [Related]

  • 15. CXCL8 Antagonist Improves Diabetic Nephropathy in Male Mice With Diabetes and Attenuates High Glucose-Induced Mesangial Injury.
    Cui S, Zhu Y, Du J, Khan MN, Wang B, Wei J, Cheng JW, Gordon JR, Mu Y, Li F.
    Endocrinology; 2017 Jun 01; 158(6):1671-1684. PubMed ID: 28387853
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct 01; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.